Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
To investigate the safety of delivering arsenic trioxide (ATO) in combination with
stereotactic radiotherapy in recurrent malignant glioma by performing an open label, Phase I
dose escalation trial. Results from this study will provide a basis for further study of ATO
combined with radiation therapy as a radiosensitizer for malignant brain tumors in future
Phase II studies.